Resources
Blog: Read the latest post
The Science of Drug Development: Lessons from a Pioneer in Pharmaceutical Decision-Making
May 5, 2025
Jay Andersen, a pioneer in pharmaceutical decision-making, shared some lessons learned from developing portfolio management and probability assessment approaches.
Webinar: Watch on-demand
Watch this webinar with Alok Tayi, PhD, Founder and CEO of Vibe Bio, to learn on how AI is accelerating the business development process, helping executive teams move faster by making it easier to collect, manage, access, and evaluate drug assets, thus empowering them to conduct more thorough due diligence with the same resources.
Additional resources
Jay Andersen, a pioneer in pharmaceutical decision-making, shared some lessons learned from developing portfolio management and probability assessment approaches.
Founding Members Chiesi, BIAL Lead Initial Funding; Landmark Bio, Uncommon Cures Join Clinical Development Network; DVLP Medicines, Vibe Bio to Provide Integrated AI-based Solutions
Pharma's business development and licensing (BD&L) teams are at the forefront of identifying new science to support their company's future. As the biopharma industry navigates an increasingly complex marketplace, traditional approaches to identifying and evaluating potential drug candidates are showing signs of strain.
Biopharma business development and scientific teams are under a lot of pressure to identify the next big program for their indication and strategy.
I recently sat down with a Top 20 pharmaceutical company to discuss their goals and struggles for the year ahead and how pharma portfolio analytics fits in.
Recently, I had a conversation with Dr. Kanya Rajangam, to discuss current perceptions about Chinese biotech, opportunities, language challenges, and risks.
Uncover new possibilities with VibeOne
Learn how VibeOne can help you discover your next indication or identify high potential development opportunities in your portfolio.
